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ABSTRACT

A radioactive microsphere for radiation therapy of a
mammal comprising a biologically compatible glass
material containing a beta or gamma emitting radioiso
tope distributed substantially uniformly throughout the
glass. Advantageously, the radioisotope is produced by
irradiation of the microsphere.
45 Claims, 5 Drawing Sheets
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RADIOACTIVE GLASS MICROSPHERES
This is a division of application Ser. No. 623,123, filed
5
Nov. 19, 1984, now U.S. Pat. No. 4,789,501.
BACKGROUND OF THE INVENTION
The present invention relates generally to microspheres useful in the treatment of cancerous and tumor
bearing tissue and more particularly to novel glass mi 10
crospheres useful in this treatment.
In the treatment of patients with certain kinds of
cancer, methods are known in which radioactive parti
cles are introduced intravascularly in order to trap the
radioactive particle at a particular site for its radiation 15
effect. According to this technique, a small quantity of
the radioactive particles are injected into the patient
and a diffuse, homogeneous field of radiation within a
selected region of the body is achieved by permanent
lodgement of the particles in the capillary bed of the 20
proposed area, typically the location of a tumor. In
early applications of this technique, yttrium oxide pow
der was suspended in a viscous medium prior to admin
istration. Yttrium was selected for the technique be
cause of its suitable characteristics: it emits nearly 100 25
percent beta radiation. See, e.g., Nolan, et al., “Intravas
cular Particulate Radioisotope Therapy”, The American
Surgeon 35: 181-188 (1969) and Grady, et. al., “IntraArterial Radioisotopes to Treat Cancer”, American
Surgeon 26 678-684 (1960). This method is not totally 30
satisfactory, however. Two disadvantages of yttrium
oxide powder are its high density (5.01 gm/cm3) and
irregular particle shape. The high density of pure yt
trium oxide powder makes it difficult to keep the parti
cles in suspension in the liquids used to inject them into 35
the body, and accelerates their tendency to settle in the
blood stream prior to reaching the desired tumor. The
sharp comers and edges of yttrium oxide particles also
irritate surrounding tissue in localized areas, and inter
fere with the uniform distribution of the radioactive 40
particles in the tumor to be treated.
In later applications, the particles used have been
microspheres composed of an ion exchange resin, or
crystalline ceramic core, coated with a radioactive iso
tope such as P-32 or Y-90. Both ion exchange resin and 45
crystalline ceramic microspheres offer the advantage of
having a density much lower than that of yttrium oxide
particles, and the ion exchange resin offers the addi
tional advantage of being particularly easy to label. See,
e.g., Zielinski and Kasprzyk, “Synthesis and Quality 50
Control Testing of 32P labelled Ion Exchange Resin
Microspheres for Radiation Therapy of Hepatic Neo
plasms”, Int. J. AppL Radial Isot 34: 1343-1350 (1983).
However, whenever a microsphere comprises a core
material having an external surface coating which con 55
tains the radioactive isotope there is a risk that the radi
oactive coating may separate from the underlying mi
crosphere core. Any mechanical breakage of the coat
ing can release unwanted radioactivity to other parts of
the human body which is highly undesirable. Further 60
disadvantages are presented by the special handling and
precautions that are necessary to coat a radioactive
isotope onto a crystalline ceramic core, or to label ion
exchange resin.
In still another application, microspheres have been 65
prepared comprising a ceramic material and having a
radioactive isotope incorporated into the ceramic mate
rial. While the release of radioactive isotopes from a
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radioactive coating into other parts of the human body
may be eliminated by incorporating the radioisotopes
into ceramic spheres, the latter product form is never
theless not without its disadvantages. Processing of
these ceramic microspheres is complicated because
potentially volatile radioactivity must be added to ce
ramic melts and the microspheres must be produced and
sized while radioactive, with concomitant hazards of
exposure to personnel and danger of radioactive con
tamination of facilities.
Consequently, a need has remained for a microsphere
which is useful in the treatment of cancer or tumor
bearing tissue, but which will not release a radioactive
coating or isotope into remote parts of the body of the
patient after administration, will not require any techni
cians to handle any radioactive materials during the
formation and spheroidization of the microsphere and
which have a density which will permit the micro
spheres to be suspended in a fluid suitable for injection
into a human.
SUMMARY OF TH E INVENTION
Among the several objects of the invention, therefore
may be noted the provision of a novel microsphere for
use in radiation therapy; the provision of such a microsphere wherein the radioactive isotope is uniformly
distributed throughout the microsphere material; the
provision of such a microsphere wherein there is no
significant release of the radioactive isotope from the
microsphere into the body of the patient; the provision
of such a microsphere in which the microsphere is com
pletely nonradioactive until irradiated for use in ther
apy; the provision of such a microsphere which con
tains a stable element or isotope that can be activated to
a beta or gamma radiation emitting isotope by neutron
irradiation; the provision of such a microsphere which
contains a number of stable elements or isotopes that
which forms a number of beta or gamma radiation emit
ting isotopes simultaneously during neutron activation,
thereby permitting wide variation in the rate at which
the radiation is delivered to the body; the provision of
such a microsphere wherein the density of the sphere is
substantially less than that of yttrium oxide particles; the
provision of formulations for treatment of tumors by
parenteral administration; and the provision of pro
cesses for radiation therapy as well as the manufacture
of microspheres of the present invention.
Briefly, therefore, the present invention is directed to
novel radioactive microspheres which may be used for
radiation therapy of a mammal. These radioactive mi
crospheres comprise a biologically compatible glass
material containing a beta or gamma radiation emitting
radioisotope distributed substantially uniformly
throughout the glass.
In another aspect, the present invention is directed to
radioactive microspheres adapted for radiation therapy
of a mammal. These radioactive microspheres comprise
a biologically compatible glass material containing a
beta or gamma radiation emitting radioisotope distrib
uted substantially uniformly throughout the glass. The
microsphere is substantially spherical in shape and has a
diameter in the range of about 5 to about 75 microme
ters.
Another aspect of the present invention is directed to
radioactive microspheres adapted for radiation therapy
of a mammal. These radioactive microspheres comprise
a biologically compatible glass material having a radioi
sotope emitting a therapeutic amount of beta or gamma
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radiation and a balance of elements which either do not
become radioactive during neutron irradiation or which
have a half-life that is sufficiently short so that the ele
ment does not emit a significant amount of beta or
gamma radiation at the time of administration.
A further aspect of the present invention is directed
to novel microspheres adapted for radiation therapy of
a mammal. These microspheres comprise a biologically
compatible glass having an isotope distributed substan
tially uniformly throughout the glass. These micro
spheres are substantially spherical in shape and the iso
tope is selected from the group consisting of phos
phorus-32 and yttrium-90 and stable isotopes which are
activatable by neutron irradiation to produce phosphous-32 or yttrium-90.
A further aspect of the present invention is directed
to novel glass microspheres adapted for radiation ther
apy of a mammal. These glass microspheres comprise
silica, alumina and yttria and have a diameter of less
than about 75 micrometers.
A still further aspect of the present invention is di
rected to a method of preparing a microsphere for use in
a radiation therapy procedure. The method comprises
irradiating a microsphere comprising a glass material
containing a stable element or isotope and thereby acti
vating the element or isotope to a beta or gamma radia
tion emitting isotope.
A still further aspect of the present invention is di
rected to a method of radiation therapy for a mammal.
This method comprises administering to the mammal,
glass microspheres containing a beta or gamma radia
tion emitting radioisotope distributed substantially uni
formly throughout the glass.
A further aspect of the present invention is directed
to novel microspheres adapted for irradiation and subse
quent use in radiation therapy of a mammal. The micro
spheres comprise a glass material containing phospho
rus or yttrium distributed substantially uniformly
throughout the glass and a balance of elements selected
from the group consisting of those elements which ei
ther do not become radioactive during neutron irradia
tion or which have a half-life that is sufficiently short so
that the element does not emit a significant amount of
beta or gamma radiation at the time of administration.
A further aspect of the present invention is directed
to novel microspheres adapted for radiation therapy of
a mammal. These microspheres comprise a glass mate
rial containing an element distributed substantially uni
formly throughout the glass and which, upon being
subjected to an effective amount of neutron irradiation,
emits a therapeutic intensity and amount of beta or
gamma radiation. The balance of elements contained by
the microsphere are selected from the group consisting
of carbon, nitrogen, oxygen, fluorine, sodium, magne
sium, aluminum, silicon, potassium, vanadium, manga
nese, gallium, niobium, iodine, lead, titanium, copper,
germanium, and zirconium.
A still further aspect of the present invention is di
rected to a radioactive glass material adapted for radia
tion therapy of a mammal. The glass material comprises
an yttrium oxide-aluminosilicate glass having a compo
sition lying substantially within a quadrilateral region of
the ternary composition diagram of the yttria-aluminasilica system. This quadrilateral region of the ternary
diagram is defined by its four corners having the follow
ing combination of weight proportions of the compo
nents: 20% silica, 10% alumina, 70% yttria; 70% silica,
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10% alumina, 20% yttria; 70% silica, 20% alumina,
10% yttria; and 20% silica, 45% alumina, 35% yttria.
A still further aspect of the present invention is di
rected to a glass material adapted for radiation therapy
5 of a mammal. The glass material comprises between
about 50 and about 70 wt. % silica, between about 1 and
about 17 wt. % alumina; between about 5 and about 9
wt. % magnesia; and between about 2 and about 10 wt.
% phosphorus pentoxide.
10

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a ternary composition diagram of the yttriaalumina-silica system with a cross-hatched region desig
nating preferred glasses for use in the microspheres of
15 the present invention.
FIG. 2 is a series of plots showing the weight propor
tion of elemental phosphorus leached from various mi
crospheres of the invention as a function of time of
exposure to deionized water at 50° C.
20
FIG. 3 is a plot similar to FIG. 2 showing leaching of
radioactive phosphorus from microspheres exposed to
human blood plasma at 37° C.
FIG. 4 is a plot of solution activity of Y-90 divided by
initial Y-90 activity versus time for a YAS glass sample
25 evaluated in Example 2.
FIG. 5 is a plot of decay of leachate from a YAS glass
sample versus time containing the results of Example 2.
30
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DESCRIPTION OF THE PREFERRED
EMBODIMENT
In accordance with the present invention, novel mi
crospheres have been devised for use in the therapy of
certain cancers and tumor bearing tissue. These novel
microspheres comprise a glass material having a stable
element which can be activated by neutron irradiation
to produce a beta or gamma radiation emitting isotope
distributed substantially uniformly throughout the
glass. Thus, these novel microspheres may be manufac
tured and sized before radioactivity is induced, thereby
avoiding the necessity of either adsorbing a radioele
ment onto the microsphere surface, or adding radioele
ments to a high temperature melt and spheroidizing and
sizing the particles while intensely radioactive.
Various biologically compatible glasses may be used
in preparing the microspheres of the present invention.
Preferably, these glasses are good solvents for small
amounts of nearly all oxides and have sufficient chemi
cal durability so that, after the microspheres are admin
istered to a target portion of the patient’s body, no sig
nificant amount of any radioactive isotope is lost from
the patient’s body or transformed to other parts of the
patient’s system. It is further preferred that the glasses
do not incorporate any elements that may cause the
microsphere to emit any significant amount of unde
sired radiation. In accordance with a preferred embodi
ment of the present invention, many aluminosilicate
glasses and lead silicate glasses have been found to be
good solvents for small amounts of nearly all oxides,
thereby permitting great versatility: the dose and profile
of the radiation emitted by microsphere may be con
trolled by incorporating elements having the desired
emission characteristics after irradiation. Many alumi
nosilicate and lead silicate glasses also have sufficient
chemical durability to prevent the loss of a significant
amount of the radioactive isotope into the patient’s
system after the microsphere is administered, yet do not
need to contain any elements that may cause the micro
sphere to emit a significant amount of undesired radia-
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tion. Various aluminosilicate glasses and lead silicate
radiation other than that emitted by Y-90 or P-32. This
glasses thus may be used in accordance with a preferred
result may be accomplished by selecting a glass compo
embodiment of the present invention. For instance,
sition that contains yttrium-89 or phosphorus-31 and a
preferred glasses incorporating yttrium are yttrium
balance of elements which either do not become radio
oxide-aluminosilicate (YAS) glass compositions lying 5 active during neutron irradiation or which have a suffi
substantially within a quadrilateral region of the ternary
ciently short half-life so as not to emit a significant
composition diagram of the yttria-alumina-silica system,
amount of beta or gamma radiation at the time of admin
the quadrilateral region being defined by the four cor
istration. Elements which either do not become radioac
ners having the following specified weight proportions
tive during neutron irradiation or which have a suffi
of each of the components:
10 ciently short half-life so as not to emit a significant
amount of beta or gamma radiation are listed in Table I
without an asterisk; those marked with an asterisk in
SiC>2
AI2O 3
Y2O 3
Table
I may form small amounts of unwanted radioac
20 %
10%
70%
tive isotopes.
70%
10%
20 %
15
70%
20 %
10%
In accordance with the present invention, the constit
20 %
45%
35%
uent elements of the glass may be chosen so that the
radiation may be tailored to deliver a radiation profile
that is ideally suited for a particular treatment. For
This quadrilateral region is shown in FIG. 1. The den
instance, in some instances it may be preferred to em
sity of the YAS glasses is preferably within the range of
about 2.7 to about 3.9 grams/cc. By way of further 20 ploy a radiotherapeutic product with short-lived beta
example, preferred glasses incorporating phosphorus
emitter Y-90, while in others it may be preferred to
comprise silica, alumina, magnesia and phosphorus con
utilize the longer-lived beta emitter P-32 or a product
taining between about 50 and about 70 wt. % silica,
that has both components. In other instances, it may be
between about 1 and about 17 wt. % alumina, between
desirable to employ a radiotherapeutic product with a
about 5 and about 9 wt. % magnesia and between about 25 gamma emitting isotope or a mixture of beta and gamma
2 and about 10 wt. % phosphorus pentoxide. The den
emitting isotopes. The microspheres of the present in
sity of the glasses incorporating phosphorus is prefera
vention permit this versatility: a combination of ele
bly within the range of about 2.2 to about 2.7 grams/cc.
ments having the desired radiation emission profile may
The microspheres of the present invention may com
be
incorporated into the glass material. In a preferred
prise essentially void-free glass microspheres, micro- 30 embodiment, a beta emitter and/or a low energy
shells, i.e., microspheres having a hollow core or glass
gamma emitting nuclide is incorporated into the micro
microspheres having a “foam-like” structure where the
spheres. In a most preferred embodiment, yttrium and
microsphere has a plurality of hollow cells. Microshells
/o r phosphorus are incorporated into the microspheres;
and microspheres having a plurality of hollow cells may
P-32 emits pure beta radiation and Y-90 emits nearly
be preferred where it is desired to employ a micro 35 pure beta radiation which will spare healthy tissue re
sphere having a density substantially less than that of
mote from the tumor site in which the microsphere is
the essentially void-free microsphere.
embedded.
Whether the microspheres of the present invention
The constituent elements of the microspheres of the
are essentially void-free, microshells, or have a plurality
present
invention are also preferably chosen so that the
40
of hollow cells, it is preferred that the microspheres be
microsphere does not contain any significant amount of
substantially spherical, i e., there are no sharp edges or
elements which have a large cross-section for neutrons.
points that would cause the microsphere to lodge in a
An example of one such element that has a large crosslocation other than that desired. In this context, elipsoisection for neutrons is boron which has a cross-section
dal and other similarly shaped particles that do not have
of 3837 bams. In a most preferred embodiment, the
45
sharp edges or points would be considered to be sub
microspheres do not contain a significant amount of any
stantially spherical in shape.
elements that have a cross-section for neutrons greater
In a preferred embodiment of the present invention,
than about 200 bams.
the constituent elements of the microspheres are chosen
The radiation dosage delivered through the use of the
so that when administered to the patient, the microspheres emit a therapeutic intensity and amount of 50 activated microspheres upon administration to the pa
tient can be varied by controlling the number of micro
short-range (e.g., a penetration of the tissue on the order
spheres administered and by controlling the amount of
of about several millimeters or less) beta or gamma
radiation emitting isotopes contained by the microradiation but will not emit a significant amount of un
spheres. The amount of radiation emitting isotopes con
wanted beta or gamma radiation which could have a
negative impact on healthy tissue surrounding the can 55 tained by the microspheres is affected by two factors:
the amount of the stable element that will be converted
cerous or tumor bearing tissue. In this regard, it is pre
to a radioelement by irradiation, and the length of time
ferred that the constituent elements of the glass be se
of irradiation. Preferably, the microspheres are irradi
lected so that the therapeutic radiation emitting radio
ated for a short period of time with an intense thermal
isotopes are the only constituent isotopes which may
emit a significant amount of radiation beyond a rela 60 neutron flux generated by a nuclear fission reactor in
stead of being irradiated for a significantly longer per
tively short period of time, e.g., on the order of about 1
iod of time with a lesser neutron flux. This technique of
week or less. Elements such as yttrium and phosphorus
a short, intense irradiation of the microsphere is particu
which form radioisotopes having a half-life greater than
larly preferred where one or more of the constituent
about two days and less than about 30 days are particu
larly preferred as the elements which emit therapeutic 65 elements of the microsphere has an undesired radiation
radiation. The balance of the constituent elements of the
profile and a half-life that is significantly greater than
glass are preferably selected so that when administered,
those constituent elements having a desired radiation
the microsphere does not emit any significant amount of
profile. Thus, the manner of irradiation may be con
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trolled in such a manner to impart the microsphere with
a therapeutic intensity and amount of radiation while
also minimizing the amount of undesired radiation.
The microspheres of the present invention may be
processed to have a size that is appropriate for the ther 5
apeutic application. The characteristics of the tissue in
which the microspheres will be embedded generally
dictate the appropriate size of the microspheres to be
employed. Generally, microspheres having a size some
where within the range of about 5 to about 75 microme 10
ters are employed for therapeutic applications and in
many cases it is preferred that the microspheres have a
size somewhere within the range of about 5 to about 50
micrometers. For instance, in the treatment of liver
cancer, it is preferred to employ microspheres having a 15
size substantially within the range of about 20 to about
30 micrometers; microspheres of this size are small
enough to be conveniently delivered to the liver
through the hepatic artery but are too large to pass
20
through the capillary bed of the liver.
The microspheres may be administered to the patient
through the use of catheters either alone or in combina
tion with vasoconstricting agents or by any other means
of administration that effectively causes the microspheres to become embedded in the cancerous or tumor 25
bearing tissue. For purposes of administration, the mi
crospheres are preferably suspended in a medium that
has a sufficient density or viscosity that prevents the
microspheres from settling out of suspension during the
administration procedure. Presently preferred liquid 30
vehicles for suspension of the microspheres include
polyvinylpyrrolidone (PVP), sold under the trade des
ignation Plasdone K-30 and Povidone by GA F Corp, a
contrast media sold under the trade designation Metrizamide by Nyegard & Co. of Oslo, Norway, a contrast 35
media sold under the trade designation Renografm 76
by E. R. Squibb & Co., 50% dextrose solutions and
saline.
The microspheres of the present invention may be
prepared from a homogenous mixture of powders (i.e., 40
the batch) that is melted to form the desired glass com
position. The exact chemical compounds or raw materi
als used for the batch is not critical so long as they
provide the necessary oxides in the correct proportion
for the melt composition being prepared. For instance, 45
if a YAS glass is being made, then yttria, alumina, and
silica powders could be used as the batch raw materials.
The purity of each raw material is preferably greater
than 99.9%. After either dry or wet mixing of the pow
ders to achieve a homogeneous mixture, the mixture 50
may be placed in a platinum crucible for melting. High
purity alumina crucibles can also be used if at least small
amounts of alumina can be tolerated in the glass being
made. The crucibles containing the powdered batch are
then placed in an electric furnace which is heated 1500° 55
to 1600° C., depending upon the composition. In this
temperature range, the batch melts to form a liquid
which is stirred several times to improve its chemical
homogeneity. The melt should remain at 1500° to 1600'
C. till all solid material in the batch is totally dissolved, 60
usually 2-5 hours being sufficient. When melting and
stirring is complete, the crucible is removed from the
furnace and the melt is quickly quenched to a glass by
pouring the melt onto a cold steel plate or into clean
water. This procedure breaks the glass into fragments, 65
which aids and simplifies crushing the glass to a fine
powder. The powder is then sized and spheroidized for
use.
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Where it is desired to use microspheres having a
diameter in the range of about 20 to about 30 microme
ters as for example in the treatment of liver cancer, it is
preferred that the quenched and broken glass be first
crushed to about minus 100 mesh particles using a mor
tar and pestle. The minus 100 mesh material is then
ground using a mechanized mortar and pestle or ball
mill, until it passes a 400 mesh sieve. The particles are
formed into glass microspheres by introducing the
—400 mesh particles into a gas/oxygen flame where
they are melted and a spherical liquid droplet is formed
by surface tension. The droplets are rapidly cooled
before they touch any solid object so that, their spheri
cal shape is retained in the solid product.
Just prior to spheroidizing, the —400 mesh powder is
rescreened through a 400 mesh sieve to destroy any
large agglomerates that may have formed during stor
age. The —400 mesh powder is then placed in a vibra
tory feeder located above the gas/oxygen burner. The
powder is slowly vibrated into a vertical glass tube
which guides the falling powder particles directly into
the hot flame of a gas/oxygen burner. Any burner capa
ble of melting —400 mesh particles of the particular
glass composition being used is satisfactory. A typical
rate for feeding the powder to the flame is 5 to 25 gm /hr
with the described apparatus. The flame of the burner is
directed into a metal container which catches the small
glass beads as they are expelled from the flame. This
container can be made of any metal which can with
stand the heat of the burner and does not contaminate
the glass. The container needs to be large enough so
that the molten spheres can cool and become rigid be
fore hitting any solid surface of the catcher container.
After spheroidization, the glass spheres are collected
and rescreened. When the microspheres are intended to
be used in the treatment of liver cancer, the fraction less
than 30 and greater than 20 micrometers in diameter is
recovered since this is the desirable size for use in the
human liver. After screening, the —30/+ 20 micro
spheres are examined with an optical microscope and
are then washed with a weak acid (HC1, for example),
filtered, and washed several times with reagent grade
acetone. The washed spheres are then heated in a fur
nace in air to 500°-600° C. for 2-6 hours to destroy any
organic material.
The final step is to examine a representative sample of
the —30/+20 spheres in a scanning electron micro
scope to evaluate the size range and shape of the
spheres. The quantity of undersize spheres (less than 10
micrometers in diameter) is determined along with the
concentration of non-spherical particles. The composi
tion of the spheres can be checked by energy dispersive
x-ray analysis to confirm that the composition is correct
and that there is an absence of chemical contamination.
The glass microspheres are then ready for irradiation
and subsequent administration to the patient.
In accordance with the present invention, the above
processing steps are merely exemplary and do not in
any way limit the present invention. For instance, those
skilled in the art will appreciate the steps involved in
producing a microshell or a microsphere having a plu
rality of hollow cells. Similarly, the present invention is
not limited to glass microspheres having a size de
scribed above; the size of the microspheres of the pres
ent invention may be varied according to the applica
tion.
In accordance with a preferred embodiment, the
microspheres of the present invention may be advanta
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geously used in the treatment of liver cancer. For this
for batch additions at 1000° C. and three to four hours
purpose, it is presently preferred to use essentially voidto refine the melt at the approximate melting tempera
free YAS glass microspheres having a composition
ture. The crucible containing the melt was quenched in
lying within the previously identified quadrilateral re
25° C. water, after which the resultant glass frit was
gion of the yttria alumina-silica composition diagram 5 broken from the crucible and ground to —100 mesh.
and that have an activity of about 0.2 to about 0.6
The —100 mesh glass powder was then slowly fed by a
Ci/gm of glass after irradiation. To achieve the desired
vibrating spatula into an oxygen/propane flame where
level of activity, the YAS microspheres are irradiated
surface tension pulled the molten particles into spheres.
for an effective period. For instance, YAS microspheres
The flow rates of oxygen and propane were adjusted for
comprising about 40% by weight yttria are irradiated in 10 each glass composition so as to yield the highest frac
a nuclear reactor to a level of about 3 Ci/gm which
tion of spherical particles. After spheroidizing, the mi
requires about 75 hours of irradiation at 1X1014 neucrospheres were wet screened with deionized water,
trons/cm2sec. Thus, by activating the microspheres to a
rinsed in acetone and dried.
level above the preferred administration range, decay of
activity of the activated microspheres may occur during 15 B. CHEMICAL DURABILITY MEASUREMENTS
processing and shipment prior to administration to the
The compositions marked with an asterisk in Table II
patient and still permit administration within the pre
were immersed in deionized water at 50° C. and the
ferred range of activity. If microshells or microspheres
release of elemental phosphorus measured as a function
comprising a plurality of hollow cells are used instead
of solid microspheres, the specific activity after irradia 20 of time. Samples of 76 to 150 p.m diameter microspheres, each sample weighing 0.5 gm, were placed in
tion needs to be higher in order to account for the de
high density polyethylene bottles with 25 ml of deion
crease in mass of similarly sized spheres. If it were pre
ized water. The bottles were then placed in an oven at
ferred to use a glass microsphere containing P-32 in
50° C .±5° C. for 7, 15, 30, and 40 days with brisk agita
stead of Y-90 for the treatment of liver cancer, the spe
cific activity required through irradiation may be con 25 tion for 5 seconds on days 2 and 27. After removing a
siderably lower than that required for Y-90 microsample from the oven, the aqueous phase was filtered
spheres; P-32 has a longer half-life than Y-90 (14.3 days
through Whatman #52 filter paper. Each filtrate was
vs. 64 hours for Y-90) which results in less decay during
then fumed with Perchloric acid (70-72%) at 75° C. to
transit and which causes it to remain active in the body
remove any soluble silica that might interfere with the
longer than Y-90.
30 spectrophotometric determination of phosphorus. In
The microspheres of the present invention may be
the determination of phosphorus, the fumed solutions
used in the treatment of liver cancer by introducing a
were mixed with an acidic ammonium vanadate, ammo
catheter into the hepatic artery and administering the
nium molybdate reagent to form a yellow vanadomoradioactive microspheres. Preferably, the microspheres
lybdate-phosphoric acid complexes. The concentration
are suspended in a medium such as Plasdone K-30 or 35 of phosphorus was calculated from the absorbence of
Metrizamide for purposes of administration. The parti
the solution measured at 400 nm.
cle density in the liver after administration is preferably
on the order of about 4000 microspheres per gram of
C.
SPECTROPHOTOMETRIC
liver. When administered in this manner, the microDETERMINATION OF PHOSPHORUS
spheres become embedded in the capillary bed of the 40
Samples of 25 ml deionized water in which 0.5 gm of
tumorous liver tissue rather than in normal liver,
microspheres
had been immersed at 50° C. for 7, 15, 30,
thereby delivering the radiation dosage primarily to the
and 40 days were prepared for determination of phos
tumor. Vasoconstricting drugs may additionally be used
phorus content. Standardized solutions of known phos
to decrease hepatic artery flow to normal liver. Microspheres used in this treatment preferably comprise ei 45 phorus ppm were prepared and their absorbence mea
surements at 400 nm. plotted. From this standardization
ther P-32 or Y-90 because of their short-ranged radia
curve, the measured absorbence values at 400 nm. from
tion.
the sample specimens were converted to ppm phospho
Other cancerous or tumor bearing tissue may simi
rus concentrations. These values were then multiplied
larly be treated with the microspheres of the present
invention. Depending upon the application, it may be 50 by dilution factors and converted to the weight of phos
phorus confirmed in the sample specimens, shown in
desirable to incorporate a gamma emitting radioisotope
Table V. Division by the weight of phosphorus in the
or a combination of gamma and beta emitting radioiso
known initial weight of glass yields the wt % of phos
topes into the microsphere. Alternatively, a physical
phorus leached given in Table V.
mixture of microspheres having different radiation pro
files may be used in order to tailor the treatment for a 55
The calibration curve becomes non-linear at very low
particular case. For instance, the treatment may com
concentrations. This uncertainty in using the calibration
prise administration of a physical mixture of two differ
line to calculate the phosphorus ppm in solution in
ent microspheres, the first type containing Y-90 and the
creases with decreasing phosphorus concentration. One
second type containing P-32.
ppm standard solutions are 4% in error by the time
The following examples illustrate the invention.
60 absorbence measurements are converted back to ppm
values from the calibration curve. This error reaches
EXAMPLE 1
6% for 0.5 ppm phosphorus standard solutions. Testing
A. MICROSPHERE PREPARATION
standards of 0.1 ppm phosphorus and converting ab
sorbence values back to ppm values by the calibration
The glass compositions listed in Table II were pre
pared from reagent grade chemicals. Batches yielding 65 curve yields errors up to 22%. Since all solutions tested
had calculated concentrations of phosphorus greater
50 grams of glass were melted in platinum crucibles in
than 0.168 ppm, it is safe to assume the maximum error
an electric furnace at the approximate temperatures in
Table II. A typical melting cycle required three hours
in the wt % phosphorus leached values to be less than

11

5,011,677

22%. The error in values decreases as the concentration
of phosphorus in the test specimen increases.
D. COMPOSITIONAL OVERVIEW
The glass compositions evaluated in this example can
be generally classified as either a modified soda-lime
silica or a magnesium aluminosilicate. In the soda-lime
compositions, the lime was eliminated so as to preclude
the formation of unwanted 45Ca, and replaced with
magnesium and/or potassium. Alumina was added to
nearly all the compositions (see Table II), to improve
the chemical durability. Compositions UMR-17 and
UMR-25 contain zirconia, which significantly improves
the resistance of other silicate glasses to alkaline attack.
Manganese dioxide was added to UMR-24 also to im
prove the resistance to alkaline attack.
In attempts to reduce the melting temperatures and
viscosity, and to keep the alkali content low, lead oxide
was included in a number of batches, and the magne
sium carbonate in the batch was replaced by magnesium
fluoride. The fluxing ability of the lead oxide additions
appeared minimal at levels less than 10 wt %. Higher
additions caused phase separation. The substitution of
magnesium fluoride for magnesium carbonate during
batching showed a slight improvement in lowering the
melt viscosity.

5

10

15

20

25

E. SPHEROIDIZATION
In composition UMR-24 large bubbles developed in
some of the microspheres during spheroidization. Dur 30
ing subsequent wet screening, the hollow microspheres
could easily be separated from the solid spheres by
floating the hollow spheres away from the heavier solid
spheres. The formation of bubbles in glass microspheres
is of interest as a means of lowering the bulk density of 35
the microspheres. Table III lists the density of currently
used essentially void-free microspheres, and the mea
sured values for the seven glass compositions evaluated
in the chemical durability tests. The higher density of
glass microspheres requires a suspending solution with 40
either a higher viscosity or higher density to prevent
settling of the microspheres prior to their use.
F. STRAY RADIATION TESTING
The compositions evaluated for chemical durability 45
were also studied after neutron irradiation to check for
the emission of undesired radiation and a low, tolerable
background of undesirable radiation was found in al
most all compositions. Only UMR-17 contained a signif
icant amount of an unwanted radioactive isotope and 50
may not be considered acceptable for use in the treat
ment of liver cancer. The unwanted radioactive isotope,
95Zr, formed from the 12 wt % zirconia in the glass. By
reducing the zirconia to 4 wt %, the unwanted radiation
was lowered to such a level that UMR-26 is acceptable 55
for this application based on this evaluation.
G. CHEMICAL DURABILITY TESTING
Results from the elemental phosphorus leaching test
are shown in FIG. 2. The wt % phosphorus leached 60
was calculated from the weight of phosphorus found in
solution, divided by the initial weight of phosphorus in
the microspheres. The decrease in phosphorus release
between glasses UMR-3 and UMR-10 is attributed to
changing the alkali from sodium to potassium, and to 65
the reduction in the total alkali content of the glass with
a corresponding increase in the silica content. The re
maining compositions are closely grouped with the high

12

zirconia containing glass, UMR-17, and the magnesium
alumino silicate, UMR-21, showing the lowest phos
phorus releases.
Any chemical corrosion of the glass microspheres by
deionized water is expected to change the solution pH.
To a limited extent the change in pH should be propor
tional to the degree of chemical reaction. The PH val
ues of the solution after 74 days at 50° C. is given in
Table IV. The higher pH values indicate UMR-3 and
UMR-25 have significantly reacted with the water rela
tive to the other compositions.
In the second durability test, the release of radioac
tive 32P was measured for the same glasses used in the
first durability test. In this test, microspheres 46 to 75
p.m in diameter were first rinsed in 0.12 N HC1 at room
temperature, rinsed in deionized water and then neutron
irradiated. After irradiation, the microspheres were
again rinsed in 0.12 N HC1, rinsed in deionized water
and transferred to vials containing 10 ml of human
blood plasma at 37° C. Samples of human blood plasma
(1.1 ml), were removed from the vials periodically and
their beta radioactivity measured with a liquid scintilla
tion counter. The activity of subsequent samples was
corrected for the decreasing volume of plasma in the
vial. In FIG. 3, the percent radioactive phosphorus
leached is the radioactivity of phosphorus in solution
divided by the decaying total of radioactive phosphorus
in the glass.
Comparison of the phosphorus leaching data in
FIGS. 1 and 2 show a good correlation in the relative
ranking of glasses evaluated. The combined information
gathered in the first durability test and pH testing is
representative of how compositions performed in the
second test, thus these methods can be used to accu
rately screen future compositions without handling
radioactive samples.
To determine the suitability of glasses based on their
release of radioactive phosphorus, a maximum value of
0.1% radioactive phosphorus leached after 30 days was
arbitrarily established. This value represents the esti
mated maximum extent of leaching from a 5% by
weight phosphorus pentoxide glass which will produce
radioactive P-32 level below the maximum level which
a healthy adult can tolerate in his body without adverse
effect.
In FIG. 3, three compositions satisfy the adopted
value of 0.1% radioactive phosphorus leached after 30
days; they are UMR-21, UMR-17, and UMR-26. As
previously noted, UMR-17 has undesirable radioactive
emissions that make it unacceptable for this application.
UMR-21 is a magnesium alumina silicate composition
which had the lowest release of phosphorus in both
leaching tests.
TABLE III
DENSITY OF TYPICAL MICROSPHERE
MATERIALS AND SELECTED GLASS SAMPLES
• Density
Material
Sample
(g/cm3)
Plastic
Ceramic*
Glass

(Polystyrene)
(bulk density)

2.00

1.05

UMR-3
UMR-10
UMR-17
UMR-21
UMR-24
UMR-25

2.41
2.35
2.56
2.55
2.37
2.38
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TABLE Ill-continued

TABLE Vi-continued

DENSITY OF TYPICAL MICROSPHERE
MATERIALS AND SELECTED GLASS SAMPLES
Density
Material
Sample
(g /cn r)
UMR-26

2.37

•3M Co., St Paul, MN

TABLE r v

5

Sample

YAS-4
YAS-5
YAS-6
YAS-7
YAS-8
YAS-9
10
YAS-10

PH OF DEIONIZED WATER
IN CONTACT WITH GLASS MICROSPHERES
AFTER 74 DAYS AT 50- C.
Sample
pH
Water Blank
UMR-17
UMR-I0
UMR-2I
UMR-26
UMR-24
UMR-25
UMR-3

4.70
7.30
7.30 (7.40)'
7.30 (7.60)'
7.45
7.90 (8.00)'
8.95 (8.95)'
9.50 (9.50)'

15
Glass

20

YAS-2
3
4
5

6
7

8
Si02

TABLE VI
Sample
YAS-1
YAS-2
YAS-3

33 21 46
55 20 55
50 20 30

3.07
3.81
3.65

3.29
2.84
3.42
3.39
3.23
3.81
3.30

•c.

Appearance

1500
1600
1500
1500
1600
1600
1600

Fluid, Clear Glass
Viscous, Opal Glass
Fluid, Clear Glass
Fluid, Clear Glass
Fluid, Opal Glass
Fluid, Clear Glass
Fluid, Clear Glass

DISSOLUTION RATES IN IN HC1 OF
YAS GLASSES AND VITREOUS SILICA
_______ Dissolution Rate (g/cm^min)_______
6 days @ 50° C. 15 days @ 30* C.
7 days @ 50* C.

io - 7
io - 7
io - 7
io - 7
28.1 x io - 7
28.3 X io - 7
7.2 X io - 7
54.6
36.2
7.8
3.4

X
X
X
X

2.8 X io - 7

2.1 X io - 7

5.7 X io - 7
3.9 X io - 7
5.0 X io - 8

6.8 X io - 7
2.8 X 10“ 7
5.5 X i o - ’
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The glass compositions listed in Table VI were pre
pared from reagent grade materials. Batches of 25 or 50
grams were melted in platinum crucibles in an electric
furnace at 1500° to 1600° C. A period of 2 to 3 hours at
temperature was allowed for fining and homogenization 30
of the melt. The glasses were cast into bars measuring
approximately 1 x 1 x 6 cm in steel molds and were
annealed at approximately 800° C. for 8 to 12 hours.
Excess glass in the crucibles was quenched in water,
broken from the crucible, and saved for spheroidizing. 35
Spheroidization of each of the glasses into microspheres
was performed according to the procedures of Example
1. Table VI also lists the density, pouring temperature
and appearance for each of the glasses identified.
The glass compositions listed in Table VI were also 40
evaluated for chemical durability with the results being
provided in Table VII. Table VII provides the dissolu
tion rate for YAS glass samples 2-8 and for vitreous
silica as determined in IN HC1 under the conditions
specified.
45
FIG. 4 reports the percent radioactive yttrium
leached from sample YAS-1 over time and under the
conditions expressed in Table VII. Each point in FIG. 4
represents the amount of radiation measured in solution
divided by the initial Y-90 activity, the ratio being ex 50
pressed as a percent. When expressed in this manner, it
is apparent that the amount of Y-90 leached from the
microsphere is well within the acceptability limit.
In FIG. 5, each point represents the measured activ
ity of leachate from sample YAS-1 over time and under 55
the conditions expressed in Table VII. Also presented
on this plot is a line representing the half-life of Y-90.
The high degree of correlation between the points and
this line demonstrate that there was not a significant
amount of any radioisotope other than Y-90 leached 60
from sample YAS-1.

Composi
Density
tion (wt %) Gm /cm 3

40 20 40
25 20 55
42 25 33
40 30 30
40 13 47
55 15 30
35 35 30

Pouring
Temp,

_________ TABLE VII__________

•Duplicate sample

EXAMPLE 2

Density
Composi
tion (wt %) Gm /cm 3

Pouring
Temp,

•c.

Appearance

1500
1550
1550

Viscous, Clear Glass
Fluid
Fluid, Clear Glass

In view of the above, it will be seen that the several
objects of the invention are achieved and other advanta
geous results attained.
As various changes could be made in the above meth
ods and products, without departing from the scope of
the invention, it is intended that all matter contained in
the above description or shown in the accompanying
drawings shall be interpreted as illustrative and not in a
limiting sense.
What is claimed is:
1. A radioactive microsphere for radiation therapy of
a mammal comprising a biologically compatible glass
material containing at least one beta or gamma radiation
emitting isotope distributed substantially throughout
the glass which emits a therapeutic intensity and
amount of beta or gamma radiation, and a balance of
elements selected from the group consisting of elements
that do not become radioactive upon neutron irradia
tion and elements that have a half-like that is sufficiently
short so that the elements do not emit a significant
amount of beta or gamma radiation at the time of admin
istration, the microsphere having a chemical durability
such that subsequent to administration of the microsphere to the mammal, the microsphere will not release
a significant amount of the radiation emitting radioiso
tope into the mammal’s system.
2. A radioactive microsphere as set forth in claim 1
wherein said glass comprises an aluminosilicate glass.
3. A radioactive microsphere as set forth in claim 1
wherein said glass comprises an yttrium oxidealuminosilicate glass.
4. A radioactive microsphere as set forth in claim 1
wherein said glass comprises a lead silicate glass.
5. A radioactive microsphere as set forth in claim 1
wherein said glass comprises an yttrium oxidealuminosilicate glass having a composition lying sub
stantially within a quadrilateral region of the ternary
composition diagram of the yttria-alumina-silica system,
65 the quadrilateral region being defined by its four cor
ners having the following combination of weight Pro
portions of the components: 20% silica, 10% alumina,
70% yttria; 70% silica, 10% alumina, 20% yttria; 70%
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silica, 20% alumina, 10% yttria; and 20% silica, 45%
alumina, 35% yttria.
6. A radioactive microsphere as set forth in claim 1
wherein said radioisotope comprises phosphorus-32.
7. A radioactive microsphere as set forth in claim 1 5
wherein said microsphere is selected from the group
consisting of essentially void-free microspheres, micro
spheres having a hollow core and microspheres having
a plurality of hollow cells.
8. A radioactive microsphere as set forth in claim 1 10
wherein said radioisotope having been formed by neu
tron irradiation of the microsphere.
9. A radioactive microsphere as set forth in claim 1
wherein said glass material is substantially free of ele
ments having a cross-section for neutrons greater than 15
about 200 bams.
10. A radioactive microsphere as set forth in claim 1
wherein said at least one beta or gamma radiation emit
ting isotope is selected from the group consisting of
isotopes having a half-like greater than about 2 and less 20
than about 30 days.
11. A radioactive microsphere as set forth in claim 1
wherein the beta or gamma radiation emitting isotope is
phosphorous-32.
12. A radioactive microsphere as set forth in claim 1 25
wherein the balance of elements are selected from the
group of elements consisting of carbon, nitrogen, oxy
gen, fluorine, sodium, magnesium, aluminum, silicon,
potassium, vanadium, manganese, gallium, niobium,
iodine and lead.
30
13. A radioactive microsphere as set forth in claim 1
wherein said glass contains between about 50 and about
70 wt. % silica, between about 1 and about 17 wt. %
alumina; between about 5 and about 9 wt. % magnesia;
and between about 2 and about 10 wt. % phosphorus 35
pentoxide.
14. A radioactive microsphere as set forth in claim 13
wherein said glass comprises a magnesium aluminosili
cate glass.
15. A radioactive microsphere as set forth in claim 13 40
wherein said glass further comprises between about 7
and about 15 wt. % K 2O.
16. A radioactive microsphere as set forth in claim 15
wherein said glass further comprises between about 2
45
and about 6 wt. % zirconia.
17. A radioactive microsphere as set forth in claim 1
wherein said radioisotope comprises yttrium-90.
18. A radioactive microsphere as set forth in claim 17
wherein said microsphere has a radiation density of
about 2 Ci/gm.
50
19. A radioactive microsphere as set forth in claim 1
wherein said microsphere is substantially spherical in
shape and has a diameter in the range of about 5 to
about 75 micrometers.
20. A radioactive microsphere as set forth in claim 19 55
wherein the beta or gamma radiation emitting radioiso
tope comprises a radioisotope selected from the group
consisting of yttrium-90 and phosphorous-32.
21. A radioactive microsphere as set forth in claim 1
wherein the balance of elements are selected from the 60
group of elements consisting of carbon, nitrogen, oxy
gen, fluorine, sodium, magnesium, aluminum, silicon,
potassium, vanadium, manganese, gallium, niobium,
iodine, lead, titanium, copper, germanium, and zirco
nium.
65
22. A radioactive microsphere as set forth in claim 21
wherein the beta or gamma radiation emitting isotope is
phosphorous-32.
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23. A radioactive microsphere adapted for radiation
therapy of a mammal comprising a glass having phosphorous-32 or yttrium-90 distributed substantially
through the glass, the microsphere having a chemical
durability such that subsequent to administration of the
microsphere to the mammal, the microsphere will not
release a significant amount of the radiation emitting
radioisotope into the mammal’s system.
24. A radioactive microsphere as set forth in claim 23
wherein said microsphere is selected from the group
consisting of essentially void-free microspheres, micro
spheres having a hollow core and microspheres having
a plurality of hollow cells.
25. A radioactive microsphere as set forth in claim 23
wherein said glass comprises an aluminosilicate glass, an
yttrium oxide-aluminosilicate glass, or a lead silicate
glass.
26. A radioactive microsphere as set forth in claim 23
wherein the microsphere has a diameter between about
5 and about 75 micrometers.
27. A radioactive microsphere as set forth in claim 23
wherein the microsphere has a diameter between about
20 and about 30 micrometers.
28. A radioactive microsphere as set forth in claim 23
wherein the microsphere has a hollow core or a plural
ity of hollow cells.
29. A radioactive microsphere as set forth in claim 23
wherein the microsphere comprises phosphorus-32.
30. A radioactive microsphere as set forth in claim 23
wherein said glass further comprises between about 50
and 70 wt. % silica, between about 1 and about 17 wt.
% alumina, between about 5 and about 9 wt. % magne
sia, between about 2 and about 10 wt. % phosphorous
pentoxide, and between about 7 and about 15 wt. %
k 2o .
31. A radioactive microsphere as set forth in claim 30
wherein said glass further comprises between about 2
and about 6 wt. % zirconia.
32. A radioactive microsphere as set forth in claim 23
wherein the microsphere has a diameter between about
5 and about 75 micrometers, and contains phosphorous32 or yttrium-90 and a balance of elements selected
from the group consisting of elements that do not be
come radioactive upon neutron irradiation and elements
that have a half-life that is sufficiently short so that the
elements do not emit a significant amount of beta or
gamma radiation at the time of administration.
33. A radioactive microsphere as set forth in claim 32
wherein the balance of elements are selected from the
group of elements consisting of carbon, nitrogen, oxy
gen, fluorine, sodium, magnesium, aluminum, silicon,
potassium, vanadium, manganese, gallium, niobium,
iodine and lead.
34. A radioactive microsphere as set forth in claim 32
wherein the balance of elements are selected from the
group of elements consisting of carbon, nitrogen, oxy
gen, fluorine, sodium, magnesium, aluminum, silicon,
potassium, vanadium, manganese, gallium, niobium,
iodine, lead, titanium, copper, germanium, and zirco
nium.
35. A radioactive microsphere as set forth in claim 32
wherein the microsphere has a hollow core or a plural
ity of hollow cells.
36. A method of radiation therapy of a mammal com
prising administering to said mammal microspheres
comprising a glass material containing a beta or gamma
radiation emitting isotope distributed substantially uni
formly throughout the glass, the microsphere having a
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chemical durability such that subsequent to administra
tion of the microspheres to the mammal, the micro
spheres will not release a significant amount of the radi
ation emitting radioisotope into the mammal’s system.
37. A method as set forth in claim 36 wherein prior to
administration the radioisotope has been formed by
irradiation of the microsphere.
38. A method of radiation therapy of a mammal com
prising embedding in the capillary bed of the mammal’s
liver microspheres comprising a glass material contain
ing a beta or gamma radiation emitting isotope distrib
uted substantially uniformly throughout the glass, the
microspheres having sufficient chemical durability so as
to avoid the release of a significant amount of radiation
emitting isotope into the mammal’s system.
39. A method as set forth in claim 38 wherein said
isotope is yttrium-90.
40. A method as set forth in claim 38 wherein said
isotope is phosphorous-32.
41. A method as set forth in claim 38 wherein said
microsphere has a diameter less than about 75 microme
ters.
42. A radioactive glass microsphere adapted for radi
ation therapy of a mammal, the glass microsphere com
prising an yttrium oxide-aluminosilicate glass contain
ing yttrium-90 and having a composition lying substan
tially within a quadrilateral region of the ternary com
position diagram of the yttria-alumina-silica system, the
quadrilateral region being defined by its four comers
having the following combination of weight propor
tions of the components: 20% silica, 10% alumina, 70%
yttria; 70% silica, 10% alumina, 20% yttria; 70% silica,
20% alumina, 10% yttria, and 20% silica, 45% alumina,
35% yttria.
43. A radioactive glass microsphere adapted for radi
ation therapy of a mammal having phosphorous-32
distributed substantially throughout the glass, the glass
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additionally containing between about 50 and 70 wt. %
silica, between about 1 and about 17 wt. % alumina,
between about 5 and about 9 wt. % magnesia, and be
tween about 2 and about 10 wt. % phosphorous pentoxide.
44. A radioactive glass microsphere adapted for radi
ation therapy of a mammal comprising, phosphorous-32
or yttrium-90 distributed substantially throughout the
glass and a balance of elements selected from the group
of elements consisting of carbon, nitrogen, oxygen,
fluorine, sodium, magnesium, aluminum, silicon, potas
sium, vanadium, manganese, gallium, niobium, iodine,
lead, titanium, copper, germanium, and zirconium, the
microsphere having a size between about 5 and about 75
micrometers and having a chemical durability such that
subsequent to administration of the microsphere to the
mammal, the microsphere will not release a significant
amount of the radiation emitting radioisotope into the
mammal’s system.
45. A biologically compatible radioactive glass mi
crosphere for radiation therapy of a mammal compris
ing at least one beta or gamma radiation emitting iso
tope having a half-like greater than about 2 and less than
about 30 days distributed substantially throughout the
glass which emits a therapeutic intensity and amount of
beta or gamma radiation, and a balance of elements
selected from the group consisting of elements that do
not become radioactive upon neutron irradiation and
elements that have a half-like that is sufficiently short so
that the elements do not emit a significant amount of
beta or gamma radiation at the time of administration,
the microsphere having a chemical durability such that
subsequent to administration of the microsphere to the
mammal, the microsphere will not release a significant
amount of the radiation emitting radioisotope into the
mammal’s system.
* * * * *
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